Testing effectiveness (Phase 2)Study completedNCT01323920
What this trial is testing
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Who this might be right for
LeukemiaLymphomaMyelodysplastic Syndrome
Dana-Farber Cancer Institute 35